Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2016 - 2025)

Ironwood Pharmaceuticals' Cash from Financing Activities history spans 16 years, with the latest figure at $122000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 100.82% year-over-year to $122000.0; the TTM value through Dec 2025 reached $216000.0, up 100.2%, while the annual FY2025 figure was $216000.0, 100.2% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $122000.0 at Ironwood Pharmaceuticals, up from $88000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $399.1 million in Q2 2023 and bottomed at -$150.3 million in Q2 2022.
  • The 5-year median for Cash from Financing Activities is $6000.0 (2025), against an average of -$3.8 million.
  • The largest annual shift saw Cash from Financing Activities surged 820.0% in 2021 before it tumbled 9508.78% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$18.6 million in 2021, then surged by 115.1% to $2.8 million in 2022, then crashed by 1914.11% to -$50.9 million in 2023, then soared by 70.75% to -$14.9 million in 2024, then soared by 100.82% to $122000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Cash from Financing Activities are $122000.0 (Q4 2025), $88000.0 (Q2 2025), and $6000.0 (Q1 2025).